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Abstract: Bronchiectasis is an airway disease characterized by thickening of the bronchial 
wall, chronic inflammation, and destruction of affected bronchi. Underlying etiologies include 
severe pulmonary infection and cystic fibrosis (CF); however, in a substantial number of 
patients with non-CF-related bronchiectasis (NCFB), no cause is found. The increasing arma-
mentarium of therapies now available to combat disease in CF is in stark contrast to the limited 
tools employed in NCFB. Our study aimed to evaluate similarities and differences in airway 
inflammatory markers in patients with NCFB and CF, and to suggest potential common treat-
ment options. The results of this study show that NCFB bronchoalveolar lavage fluid samples 
possessed significantly increased NE activity and elevated levels of matrix metalloproteinases 
2 (MMP-2) and MMP-9 compared to healthy controls (P , 0.01); however, the levels detected 
were lower than in CF (P , 0.01). Interleukin-8 (IL-8) concentrations were significantly elevated 
in NCFB and CF compared to controls (P , 0.05), but in contrast, negligible levels of IL-18 
were detected in both NCFB and CF. Analogous concentrations of IL-10 and IL-4 measured 
in NCFB and CF were statistically elevated above the healthy control values (P , 0.05 and 
P , 0.01, respectively). These results indicate high levels of important proinflammatory markers 
in both NCFB and CF and support the use of appropriate anti-inflammatory therapies already 
employed in the treatment of CF bronchiectasis in NCFB.
Keywords: bronchiectasis, cystic fibrosis, proteases, inflammation
Introduction
Bronchiectasis is a respiratory disease characterized by dilated thick-walled  bronchi, 
periods of acute infective exacerbations, inflammation, and purulent sputum 
 expectoration. The cycle of infection and inflammation results in permanent lung tis-
sue damage and remodeling. Causes or genetic conditions leading to the development 
of bronchiectasis include immunodeficiency, primary ciliary dyskinesia or severe 
pulmonary infection, but the most common cause of bronchiectasis in children is 
cystic fibrosis (CF).1
In the United States, the prevalence of non-CF-related bronchiectasis (NCFB) in the 
older population (.65 years) now stands at 1106 cases/100,000 persons and is increas-
ing at a rate of 8.7% per year from the year 2000 through to 2007 with consequent costs 
to health care delivery.2 Indeed, the prevalence and severity of NCFB intensifies with 
age and when in association with other diseases or autoimmune symptoms, including 
chronic obstructive pulmonary disease (COPD) or rheumatoid arthritis respectively, 
the relative risk of death increases.3,4 In COPD, bronchiectasis has been reported in 
50% to 57% of patients.5–7
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On many levels, the pathogenesis of CF lung disease and 
the properties of CF airway secretions are comparable to those 
of NCFB. For example, CF is caused by mutations in the 
CF transmembrane conductance regulator chloride channel, 
which results in increased epithelial sodium channel (ENaC)-
mediated ion absorption in the superficial airway epithelial.8,9 
In concurrence, it has been shown that some patients with 
idiopathic bronchiectasis carry a mutation in the ENaC β or 
γ genes, resulting in a defective ENaC protein.10 Moreover, 
lower respiratory tract infections with Gram-negative bacteria 
including Pseudomonas aeruginosa are a major cause of mor-
bidity and mortality among patients with CF and NCFB and 
are associated with worsening lung function and an excess loss 
in forced expiratory volume in 1 second (FEV
1
).11,12 Patients 
with CF and NCFB experience excessive neutrophilic infiltra-
tion resulting in delivery of high levels of enzymes such as 
neutrophil elastase (NE) to the airways, the latter playing a 
pivotal role in the destruction of lung tissue.13,14 The inflam-
matory response within the airways is dependent upon the 
interplay between proinflammatory and anti-inflammatory 
cytokines. Proinflammatory mediators, which favor neutro-
phil trafficking to the bronchial lumen, include interleukin-8 
(IL-8), IL-1 and tumor necrosis factor-α (TNF-α). IL-8 is 
markedly increased in CF bronchial samples15,16 and in NCFB 
a significant correlation has been recorded between high-
resolution computed tomography (HRCT) severity scores 
and sputum IL-8 and TNF-α levels.17 In response to TNF-α, 
neutrophils also release matrix metalloproteinases (MMPs),18 
which have the potential to augment inflammation and cause 
extensive airway remodeling.19,20 Increased levels of MMP-8 
and MMP-9 have been reported in bronchoalveolar lavage 
(BAL) fluid of both CF and NCFB subjects.21–24
Despite the reported similarities, CF and NCFB are quite dis-
tinct and respond differently to clinical management. For exam-
ple, as high concentrations of DNA contribute to the viscosity 
of CF airway secretions, treatment with recombinant human 
DNase (rhDNase), an enzyme which cleaves DNA polymers, 
results in a significant decrease in the viscosity of mucopurulent 
sputum in CF25 and has demonstrated an improved in FEV
1
.26–28 
In contrast, in adults with idiopathic bronchiectasis, treatment 
with rhDNase has been shown to have a negative effect on FEV
1
 
and has led to increased pulmonary exacerbations.29,30
Until recently, no guidelines existed to direct the clini-
cian to the optimum diagnosis, investigation, and treatment 
options available for NCFB due to the relative paucity of 
well-controlled clinical trials and basic science research. 
Even now, the lack of well-designed clinical trials concerning 
the management of NCFB prevents the transfer of existing 
treatment options for CF bronchiectasis for use in patients 
with NCFB. To date, clinical reports have focused on differ-
ences between CF or NCFB airway inflammatory markers 
compared to healthy control individuals, but relatively few 
studies have directly compared CF to NCFB. Most impor-
tantly, there is now an urgency to understand the similarities 
and differences between these two diseases to identify the 
common or different treatment options. To this end, the pres-
ent study was designed to directly compare airway inflam-
matory markers in patients with CF to NCFB.
Materials and methods
Chemicals
All chemicals and reagents were purchased from Sigma 
Aldrich Chemical Co, Ltd (Dublin, Ireland), unless indicated 
otherwise.
Patient recruitment and BAL  
fluid sample collection
Prior to recruitment, nonsmoking patients had to be exacerbation-
free over the preceding 6-week period. There were 6/10 and 
5/10 males recruited to the NCFB and CF study, respectively 
(Table 1). The median and interquartile range of the age was 
65 (51.5–71.5) and 22.50 (20.50–26.5) years for the NCFB and 
CF groups, respectively. Pulmonary function tests revealed a 
median FEV
1
 of 71% (range 47%–95%) in the NCFB group. 
In all study patients, the diagnosis of bronchiectasis was made 
by HRCT using well-established criteria.31
The underlying cause of NCFB was postinfectious in 
five patients (including pertussis infection), immunoglobulin 
G subclass 1 deficiency in one, and in the remaining patients 
no cause was identified (total n = 10 patients). No patients were 
identified as having alpha-1 antitrypsin deficiency. Exclusion 
criteria for NCFB patients were: exacerbation of bronchiectasis 
in the last 6-week period; current smokers; documented history 
of COPD, congestive cardiac failure, or neuromuscular disorder 
which could lead to altered spirometry; or any inflammatory dis-
order associated with abnormal inflammatory markers. CF was 
excluded by at least two negative results of sweat tests conducted 
in patients with a clinical presentation compatible with CF.32,33 
Microbiology results showed that two patients with NCFB were 
positive for Moraxella catarrhalis and two for P. aeruginosa.
Inclusion criteria for the CF cohort of patients required 
a confirmed diagnosis of CF by sweat chloride con-
centrations . 60 mmol/L on at least two separate occasions 
and subsequent confirmatory genotyping. CF patients (n = 10) 
were heterozygous for the ∆F508 mutation and illustrated a 
median FEV
1
 of 39% (23%–53%). Patients with CF were 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
Bergin et al
Journal of Inflammation Research 2013:6
colonized with Aspergillus fumigatus (n = 3) or P. aeruginosa 
(n = 5). One patient was cocolonized with A. fumigatus 
and P. aeruginosa and one patient with A. fumigatus, 
Stenotrophomonas maltophilia, and Staphylococcus aureus.
BAL fluid samples were collected from patients attending 
Beaumont Hospital. This study complied with the tenets of 
the Declaration of Helsinki and full informed consent was 
obtained preprocedure according to a protocol approved by 
the Beaumont Hospital Ethics Committee. BAL fluid was 
obtained from adult individuals with CF (n = 10), NCFB 
(n = 10), sarcoidosis (n = 10), or healthy control volunteers 
(n = 10). BAL fluid samples (10 mL) were obtained by wedg-
ing the bronchoscope into the most abnormal appearing lobe 
identified by reviewing the HRCT images and visual inspec-
tion during bronchoscopy. Sterile normal saline was instilled 
into this abnormal lobe and was suctioned immediately into 
a trap. The sample was then split and half was sent for micro-
biological examination, total cell count, and differential count. 
The remaining half was centrifuged at 1000 g for 10 minutes. 
The resulting cell-free supernatants were aliquoted and stored 
frozen at −80°C for subsequent analysis.
Cell counts and NE activity  
in CF BAl fluid
The total cell count and enumeration of neutrophil and 
macrophages in BAL fluid was as described previously.34 
NE activity was quantified using an NE-specific substrate, 
N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide (R&D 
Systems, Minneapolis, MN, USA) as described previ-
ously.35 NE activity was quantified in 15 µL of BAL fluid 
at 405 nm. BAL fluid samples were measured for protein 
with Bio-Rad protein assay (Bio-Rad, Richmond, CA, 
USA) and NE activity among patient and healthy control 
samples expressed as Units (U)/µg of BAL fluid protein.
Gelatinase zymography
Gelatin zymography was performed on BAL fluid samples 
as described previously.35 Protein concentration was 
determined and 500 ng of BAL fluid was incubated for 
10 minutes in nonreducing sample buffer (0.25% [w/v] 
bromophenol blue, 50 mM Tris, pH 7.5, 40% [v/v] glycerol 
and 1% [w/v] sodium dodecyl sulfate [SDS]). Samples 
and molecular weight markers (BioRad Precision Plus 
Protein Standard; Bio Rad) were electrophoresed on a 7% 
SDS-polyacrylamide gel electrophoresis containing gelatin 
(1 mg/mL). After electrophoresis, the gels were incubated 
in 50 mM Tris (pH 7.5), 5 mM CaCl
2
, 1 µM ZnCl
2
 con-
taining 2.5% (v/v) Triton X-100 for 30 minutes at room 
temperature. The gels were washed in the same buffer 
without the Triton X-100 for 5 minutes and then incubated 
at 37°C overnight in the same buffer supplemented with 
1% (v/v) Triton X-100. To visualize gelatinases, gels were 
stained with Coomassie blue stain (0.2% [w/v]  Coomassie 
brilliant blue, 45% [v/v] methanol, 10% [v/v] acetic acid) 
and then destained (25% [v/v]  methanol, 10% [v/v] acetic 
acid). Gelatinases appeared as translucent bands on gels 
Table 1 Characteristics of patients included in BAL studies
CF NCFB Control
No of subjects 10 10 10
Sex, % male/female 50/50 60/40 60/40
Age, years 22.5 (20.5–26.5) 65 (51.5–71.5) 25 (22.5–33)
FEV1, % predicted 40 (25.5–49.5) 83.5 (53.5–95) 99 (91–110)
Genotype ∆F508 heterozygous – –
Serum protein levels
Alpha-1 antitrypsin (mg/ml) 1.26 (0.86–1.94) 1.42 (1.34–1.51) –
IgG (6.0–15.0) 18.9 (13.45–18.9) 11 (8.56–13) –
IgA (0.7–4.0) 2.73 (0.41–6.1) 2.63 (1.39–3.52) –
IgM (0.5–2.3) 1.29 (0.53–2.29) 0.66 (0.16–1.21) –
Bacteriology AF (n = 3) 
PA (n = 5) 
AF + PA (n = 1) 
AF + SM + SA (n = 1)
MC (n = 2) 
PA (n = 2)
–
BAL cells (min–max)
Total cells × 103/mL 1021 (196–3257) 243 (10–1086) –
Neutrophils (%) 73 (60–80) 67 (56–88) –
Macrophages (%) 20 (10–36) 27 (8–38) –
Note: Results are expressed in medians and interquartile ranges unless otherwise stated. 
Abbreviations: BAl, bronchoalveolar lavage; CF, cystic fibrosis; NCFB, non-CF bronchiectasis; FEV1, forced expiratory volume in 1 second; Ig, immunoglobulin; 
AF, Aspergillus fumigatus; PA, Pseudomonas aeruginosa; SM, Stenotrophomonas maltophilia; MC, Moraxella catarrhalis; SA, Staphylococcus aureus.
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ranging from approximately 175 kDa to 62 kDa. As previ-
ously described, bands at approximately 85 kDa and 72 kDa 
potentially representing MMP-936 and MMP-2,37 respec-
tively, were quantified by densitometry using the Syngene 
G:BOX Chemi XL gel documentation system (Syngene, 
Cambridge, UK).
Quantification of BAl  
fluid cytokine levels
Concentrations of IL-8, IL-18, IL-10, and IL-4 in BAL 
fluid samples were measured by ELISA (R&D Systems). 
Cytokine concentrations were expressed as pg/mg of BAL 
fluid protein.
Statistical analysis
The data were analyzed with GraphPad Prism (version 4.03 
for Windows; GraphPad Software, San Diego, CA, USA) 
and results are expressed as median value. The groups were 
compared by two-tailed independent sample Student’s t-test 
when normally distributed or by the nonparametric Mann–
Whitney U test, as appropriate. A P-value , 0.05 was deemed 
statistically significant.
Results
Comparative quantification of NE  
activity in CF, NCFB, and healthy  
control BAl fluid samples
Quantification of NE activity by fluorometric analysis 
revealed a significant difference in NE activity between all 
three groups (P , 0.01), with the highest level detected in 
BAL fluid from patients with CF (110.2 × 104 U/µg BAL 
fluid) (Figure 1). BAL fluid samples from individuals with 
NCFB illustrated an intermediate level elevated above the 
healthy control values (9.312 × 104 and 1.5 × 104 U/µg BAL 
fluid respectively; P , 0.01), but also statistically lower 
than the CF cohort (P , 0.01). In line with these results, 
NCFB BAL fluid contained a significantly lower number 
of neutrophils compared to CF (162 × 103/mL compared to 
745 × 103/mL, respectively; P , 0.01).
Increased MMP-2 and MMP-9 levels  
in CF and NCFB BAl fluid samples
Previous studies have demonstrated the impact of NE 
on MMP-2 expression38 and a correlation exists between 
MMP-9 and NE activity.23 This led us to evaluate MMP-2 and 
MMP-9 levels in bronchoalveolar samples by  zymography. 
 Representative SDS-PAGE zymograms indicating BAL fluid 
gelatinase levels in healthy control volunteers, NCFB or CF 
are shown in Figure 2A–C. Results of densitometry analysis 
of a 72 kDa gelatinase band, assumed to represent MMP-2 
(Figure 2D) and an 85 kDa band, potentially MMP-9 
(Figure 2E), are indicated in the respective scatter plots. 
 Statistically significant differences in median relative BAL 
fluid MMP-2 levels were observed in CF and NCFB in com-
parison to healthy control volunteers (85.8, 16.8, and 0.40, 
respectively; P , 0.01). The difference in median relative 
BAL fluid MMP-2 levels between NCFB and CF was also 
statistically significant (P , 0.01). Median relative BAL fluid 
MMP-9 levels were higher in CF (101.5) and NCFB (65.78) 
in comparison to healthy control volunteers (0.74), and 
were also statistically different from each other (P , 0.01). 
Collectively these results provide evidence for dysregulated 
MMP-2 and MMP-9 levels in NCFB, albeit at a level lower 
to that detected in CF.
Comparative quantification of Il-8 and 
Il-18 in CF and NCFB BAl fluid samples
NE has been shown to upregulate proinflammatory cytok-
ines including IL-8 expression and secretion from bronchial 
epithelial cells39,40 and negatively impact IL-18 protein 
integrity.16 For this reason we compared the levels of IL-8 
and IL-18 in CF and NCFB BAL fluid. IL-8 measurements 
by ELISA revealed statistically significant differences in 
median BAL fluid IL-8 concentrations in CF (400.5 pg/mg 
of BAL fluid) and NCFB (282.3 pg/mg of BAL fluid) when 
compared to healthy control volunteers (P , 0.01 and 
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Figure 1 Comparative quantification of neutrophil elastase (NE) activity in CF and 
NCFB BAl fluid. 
Notes: NE activity levels in BAl fluid of healthy control volunteers (n = 10), 
patients with CF (n = 10) and NCFB (n = 10) were compared. Individual points are 
from separate subjects (**P , 0.01) and horizontal bars represent median values. 
NE activity was significantly increased in CF and NCFB compared to healthy control 
samples.
Abbreviations: BAl, bronchoalveolar lavage; CF, cystic fibrosis; hC, healthy 
control volunteers; NCFB, non-CF bronchiectasis; NE, neutrophil elastase.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4
Bergin et al
Journal of Inflammation Research 2013:6
P , 0.05, respectively). The difference in median BAL 
fluid concentrations of IL-8 between NCFB and CF was also 
statistically significant (P , 0.05). This set of experiments 
demonstrates that IL-8 levels in NCFB are at a level inter-
mediate to the healthy control and CF groups. In contrast, CF 
and NCFB BAL fluid IL-18 levels were consistently low and 
no significant difference was observed when compared to the 
healthy control volunteers (Figure 3B). As a positive control 
for this experiment BAL fluid from parents with sarcoidosis 
was employed, as this has previously been shown to contain 
high levels of IL-18.41
Il-10 and Il-4 protein levels are similar  
in CF and NCFB BAl fluid samples
Previous studies have revealed the prevalence of high levels of 
anti-inflammatory cytokines within the CF airways.42,43 Con-
sequently, we next compared the levels of IL-10 and IL-4 in 
CF BAL fluid to NCFB samples. Results of ELISA analysis 
of IL-10 and IL-4 are indicated in Figure 4.  Statistically 
significant differences in BAL fluid IL-10 median levels 
were observed in CF and NCFB in comparison to healthy 
control volunteers (75.62, 151.3, and 0.1 pg/mg,  respectively; 
P , 0.05) (Figure 4A). The difference in IL-10  levels 
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Figure 2 MMP-2 and MMP-9 levels in CF and NCFB BAl fluid. (A–C) Gelatinase levels in BAl fluid from healthy controls (A; HC, n = 10), NCFB (B, n = 10) and patients 
with CF (C, n = 10) were compared, with each lane representing BAl fluid from a separate subject. BioRad Precision Plus Protein Standard was electrophoresed and is 
indicated on the left. Putative MMP-9 (85 kDa) and MMP-2 (72 kDa) bands are indicated by the arrows. Results of densitometry analysis of MMP-2 (D) and MMP-9 (E) levels 
are indicated in the respective scatter plot (**P , 0.01). 
Note: MMP-2 and MMP-9 were significantly increased in CF and NCFB compared to healthy control samples.
Abbreviations: BAl, bronchoalveolar lavage; CF, cystic fibrosis; hC, healthy control volunteers; MMP, matrix metalloproteinase; NCFB, non-CF bronchiectasis.
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Figure 3 Il-8 and Il-18 levels in BAl fluid. BAl fluid proinflammatory Il-8 (A) and Il-18 (B) concentrations were determined by sandwich ElISA. 
Notes: Patients with CF (n = 10), NCFB (n = 10), sarcoidosis (sarcoids, n = 8), and healthy control volunteers (hC, n = 10) were compared in the respective ElISAs. 
Sarcoidosis samples were used as a positive control for the Il-18 ElISA. All values points are from separate subjects (*P , 0.05; **P , 0.01) and presented as pg/mg of BAl 
fluid protein. horizontal bars represent median values.
Abbreviations: BAl, bronchoalveolar lavage; CF, cystic fibrosis; hC, healthy control volunteers; Il, interleukin; NCFB, non-CF bronchiectasis.
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between NCFB and CF was not statistically significant 
(P = 0.9). Median BAL fluid IL-4 levels were higher in CF 
(12.55 pg/mg) and NCFB (28.38 pg/mg) compared to healthy 
control samples (2.12 pg/mg), but were not statistically dif-
ferent from each other (P = 0.9) (Figure 4B). Collectively 
these data indicate that in contrast to disproportionate levels 
of proteases and proinflammatory IL-8 levels (Figures 1–3), 
these results provide evidence for analogous concentrations 
of anti-inflammatory cytokines including IL-4 and IL-10 in 
NCFB and CF bronchial samples.
Correlation of NE and MMP-9 with FEV1 
in CF and NCFB BAl fluid samples
Many studies have shown reduced FEV
1
 to be associated with 
increased inflammatory markers in respiratory diseases.44–47 
Our study compares two diseases with similar manifesta-
tions but with different pathogenesis and this dichotomy 
is evident when we look at the result of NE with respect 
to FEV
1
 (Figure 5A). Individuals with NCFB clearly have 
higher median FEV
1
 (83.5% versus 40% in CF) in associa-
tion with greatly reduced median NE when compared with 
CF. In fact the median NE is reduced by a factor of approxi-
mately ten times in the NCFB compared to the CF group 
defining a separate region in the graphic (110.2 × 104 versus 
9.312 × 104 U/µg BAL fluid). Nevertheless there is a poor, 
but statistically significant, correlation of NE with declining 
FEV
1
 (r2 = 0.2660; P = 0.01). This difference in NE may be 
explained by the difference in the total neutrophil number 
seen in NCFB BAL fluid compared to CF (Table 1). When we 
examine the relationship between FEV
1
 and the neutrophil-
derived MMP-9, a similar, but not as marked, separation 
is evident, with NCFB demonstrating higher FEV
1
 with 
lower MMP-9 than CF BAL fluid (Figure 5B). A significant 
correlation between falling FEV
1
 and increasing MMP-9 
exists (r2 = 0.4646; P = 0.01) which is likely a surrogate 
marker of the degree of severity of illness and frequency of 
exacerbation in CF over that seen in NCFB.
Discussion
In this study, we evaluated the levels of airway inflammatory 
markers in adults with CF and NCFB. The results indicate 
high levels of inflammatory markers in both CF and NCFB 
airway samples and although divergent activity of proteases 
and proinflammatory IL-8 levels were detected, which may 
be explained by neutrophil number and severity of disease, 
respectively, comparable levels of the anti-inflammatory 
cytokines IL-10 and IL-4 were present in CF and NCFB 
bronchial samples.
The airway microbiome within the CF and NCFB milieu 
involves recognized pathogens such as P. aeruginosa,11,12,48 
Streptococcus pneumoniae, Haemophilus influenzae,49 
S. maltophilia, and S. aureus and/or colonization by 
the filamentous fungi A. fumigatus.50 Bacterial-released 
enzymes including Pseudomonas pseudolysin (elastase) 
and aeruginolysin (alkaline protease) have been shown to 
proteolytically cleave and inactivate the antiprotease elafin51 
and to completely degrade IL-18.16 However, the presence 
of inflammation in the absence of detectable microbes in 
the CF52 and NCFB14 airways has also been described. 
Indeed, six of the 10 NCFB patients recruited to this study 
were free from microbial colonization, yet presented with 
high levels of NE-enhanced inflammation. Although lower 
levels of NE activity were detected in samples of BAL 
fluid from NCFB compared to CF individuals, within the 
airways the persistently dominant activity of NE can lead to 
degradation of structural matrix proteins including elastin, 
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Figure 4 Il-10 and Il-4 levels in BAl fluid. 
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collagen, and proteoglycans.13 As demonstrated in this study 
(Figure 5A), NE concentrations in NCFB sputum have been 
shown to correlate positively with neutrophil cell numbers14 
and negatively with lung function in CF and NCFB.53 Our 
study illustrates two distinct patterns of NE in NCFB and 
CF BAL fluid, which may be explained by the difference in 
total neutrophil numbers. The decreased neutrophil number 
in our NCFB BAL fluid samples could in turn lead to reduced 
neutrophil-derived DNA in the airway, in part clarifying the 
previously described lack of successful treatment of NCFB 
with rhDNase.30
In this paper, we also compared the presence of two 
MMPs in BAL samples, with MMP-9 and MMP-2 levels 
in NCFB illustrating an intermediate range between those 
detected in CF and healthy control samples. These data are 
in contrast to a previous study that found no significant dif-
ference in the level of MMP-9 in exhaled breath condensate 
of children with CF compared to NCFB.54 This variance in 
results is possibly due to the zymographic detection of gelati-
nase levels in BAL fluid in our study, compared to the use of 
ELISA in the study by Karakoc et al.54 Indeed, both MMP-9 
and MMP-2 are secreted as an inactive proform and a role 
for neutrophil-derived serine proteases in their activation has 
been described.23,55 A previous study has established a strong 
correlation between NE and MMP-9 activity in CF samples23 
and incubation of human HT-1080 cells with either NE, cathe-
psin G or proteinase-3 resulted in pro-MMP-2 activation, an 
effect reversed by inclusion of the serine protease inhibitor 
alpha-1 antitrypsin.55 When we examined the relationship of 
FEV
1
 to the neutrophil-derived MMP-9 (Figure 5B), a clear 
correlation of increasing MMP-9 levels with falling FEV
1
 
was observed. Moreover, MMP-2 has been implicated in the 
pathogenesis of a number of pulmonary disorders including 
COPD and asthma.56 Recently we have demonstrated that 
NE can augment MMP-2 expression, potentially leading to 
an increased inflammatory response within the CF airways, 
with important implications for antiprotease therapeutic 
intervention.38
A number of comprehensive studies have evaluated the 
cytokine profile, including IL-8 levels in lungs of children and 
adults with CF.42,57 Compared to healthy control volunteers, 
within the present study we found that IL-8 concentrations 
are elevated in both CF and NCFB airway samples, although 
a significant difference was apparent between the two patient 
groups with lower levels detected in NCFB. The levels of 
IL-8 detected in NCFB compared to healthy controls is in 
agreement with a previous report demonstrating a positive 
correlation between sputum IL-8 levels and NCFB symp-
tom scores, and a negative correlation with lung function.17 
Of interest, a recent study found no significant difference 
in sputum IL-8 levels in NCFB patients who were either 
Pseudomonas colonized or noncolonized, suggesting IL-8 as 
a potential target for anticytokine therapy.14 Moreover, exces-
sive neutrophilic inflammation in CF is partially explained 
by the stability of IL-8 within the lung. The aforementioned 
stability has been attributed to the capacity of IL-8 to bind 
glycosaminoglycans, which are overexpressed within the CF 
airways,58–62 although a similar phenomenon in NCFB has 
yet to be explored. Hypertonic saline is now a cornerstone 
of airway clearance therapy in CF and until recently has 
been considered primarily as an airway hydration therapy. 
However, a new mechanistic study has shown that hypertonic 
saline also posseses immunomodulatory properties as it dis-
rupts the interaction between glycosaminoglycans and IL-8, 
rendering IL-8 more susceptible to proteolytic degradation, 
thus helping to resolve inflammation in the airway.63 In this 
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Figure 5 Correlation between NE activity and MMP-9 levels with FEV1. Correlation between NE activity (A) or MMP-9 levels (B) and FEV1 in CF (•) and NCFB (○). 
(A) A significant correlation of NE with declining FEV1 (r
2 = 0.2660, P = 0.01) was observed. (B) A significant correlation between declining FEV1 and MMP-9 was recorded 
(r2 = 0.4646, P = 0.01).
Abbreviations: BAl, bronchoalveolar lavage; CF, cystic fibrosis; FEV1, forced expiratory volume in 1 second; HC, healthy control volunteers; MMP, matrix 
metalloproteinase; NCFB, non-CF bronchiectasis; NE, neutrophil elastase.
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light, the use of hypertonic saline in NCFB appears to hold 
great promise as the present study shows that the airways hold 
similar increased levels of IL-8 to CF bronchiectasis.
In contrast to IL-8, IL-18 binds poorly to glycosamino-
glycans and is highly sensitive to proteolytic degradation.16 
Reduced IL-18 protein levels have previously been described 
in CF BAL fluid samples16,64,65 and it has been reported that 
IL-18 degradation and clearance occurs within minutes after 
exposure to serine proteases including NE and cathepsin 
G.16 The susceptibility of IL-18 to serine protease degrada-
tion may explain why no IL-18 was detected in NCFB BAL 
fluid. Reduced T
H
1 response to microbial infection has been 
correlated with IL-18 deficiency66 and hence this study sug-
gests that a strategy leading to a reduction in levels of serine 
protease activity, such as nebulized antiproteases,67 may 
positively affect IL-18 stability and improve the pulmonary 
outcome of microbial-infected CF and NCFB individuals. 
Indeed, the concept of strategies which decrease serine 
protease activity has had some initial success in CF bron-
chiectasis where inhalation of alpha-1 antitrypsin over 4 
weeks has been shown not only to reduce free elastase, but 
also the proinflammatory mediators IL-8, TNF-α, IL-1β, 
and LTB
4
.68
The biological activity of IL-4 and the T
H
2 bias of CF 
lymphocytes have been comprehensively studied by a number 
of investigators.43,69 Within the present study we observed 
that IL-4 is equally expressed at high levels in CF and NCFB 
BAL fluid compared to healthy control samples. As pulmo-
nary protein levels of IL-4 have previously been shown to 
inversely correlate with lung function in CF,43 these findings 
may have implications for patients with NCFB. IL-10 is also 
an important anti-inflammatory mediator that functions to 
inhibit production of cytokines by T lymphocytes, modulates 
IL-8 production by macrophages, and promotes resolution 
of lung inflammation by promoting neutrophil apoptosis. 
Within this study, we observed equal protein expression of 
IL-10 in CF and NCFB, with recorded levels statistically 
increased above the median of the healthy control. This result 
is in contrast to those demonstrating that IL-10 was signifi-
cantly depressed and differed little from healthy controls.43 
However, our data are supported by two other studies which 
demonstrated significantly higher levels of IL-10 present in 
BAL fluid42 and sera65 from infected and uninfected patients 
with CF when compared to either pristine or disease control 
subjects.
A number of limitations to this study should be discussed. 
Firstly, the differences observed between CF and NCFB in this 
study may in part be explained by the greatly reduced FEV
1
, 
extent or severity of bronchiectasis, and the presence of 
airway bacterial colonization including P. aeruginosa infec-
tion present in the CF lung. Secondly, the patient number 
recruited is small due to strict inclusion and exclusion criteria 
and single-hospital nature of this study and the patients are 
not well matched for age. The above factors may limit the 
generalizability of the study results and conclusions. Larger 
multicenter studies looking at airway inflammatory mark-
ers in the two diseases and randomized controlled trials of 
specific therapies are required. Thirdly, BAL samples were 
acquired from the most affected lobe identified by HRCT and 
visual inspection for both the CF and NCFB groups, given 
that it is well recognized that inflammation and severity of 
disease are heterogeneous in NCFB the results may reflect 
the worst case scenario for inflammation in NCFB rather than 
reflect the whole lung condition as seen in the more homog-
enous inflammation observed in CF bronchiectasis.
Despite these limitations however, many similarities in 
inflammatory markers exist, which suggests that the existing 
strategy of transferring therapies from the CF population 
to the NCFB population carries significant merit despite 
the obvious exception of rhDNase.30 Further work is sug-
gested by this study, for example a prospective assessment 
of inflammatory markers before and after P. aeruginosa 
eradication to elucidate the pathogenesis of this important 
pathogen. Azithromycin, a macrolide antibiotic and well-
established treatment for patients with CF bronchiectasis 
who are colonized with Pseudomonas is now emerging as 
a treatment for COPD, asthma, and bronchiolitis obliterans 
where it is used as a novel anti-inflammatory.70–74 Indeed a 
recently published study by Wong et al, does suggest that 
azithromycin treatment may prove beneficial in the preven-
tion of exacerbations in individuals with NCFB.75 In contrast 
to CF, FEV
1
 in NCFB remains a poor indicator of disease 
response to treatment; therefore along with patient related 
outcomes, time to exacerbation and number of exacerbations, 
airway proinflammatory cytokine release may find a place as 
a surrogate marker of successful treatment. In conclusion, 
these data suggest that therapeutic strategies pertinent to CF 
bronchiectasis, including anti-inflammatory therapies, are of 
potential benefit in treatment of NCFB.
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